PUBLISHER: Polaris Market Research | PRODUCT CODE: 1424031
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1424031
The global herpes simplex virus treatment market size is expected to reach USD 4.66 billion by 2032, according to a new study by Polaris Market Research. The report "Herpes Simplex Virus Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Herpes Simplex Virus-1, Herpes simplex virus-2); By Drug; By Vaccine; By Route of Administration; By End-use; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The higher transmission potential of viruses is forcing government agencies and people to get treatment as quickly as possible. Herpes simplex is a virus that is divided into two types based on the infection rate among humans. HSV-1 is usually transmitted through skin-to-skin contact from the infected person. At the same time, HSV-2 is an oral herpes that mostly infects children during childhood due to non-sexual contact with the saliva of infected people. One of the major factors driving the need for efficient treatment of the herpes simplex virus is that if a person gets infected once, then it can last forever.
The herpes simplex virus builds a latent network once it gets inside the human body. While it is likely to vanish after a week to ten days, it can cause painful blisters on the skin around the nose and mouth. In some cases, herpes simplex may lead to harmful brain inflammation and eye infections. According to the World Health Organization, the herpes simplex virus is a more common disease in society, affecting about two-thirds of the world population. This is emphasizing the essence of herpes simplex virus treatment in the global market.
The growing research and development activities to innovate new therapies with the potential to cure herpes simplex virus treatment are expected to showcase significant growth opportunities in the market. For instance, a 2023 study published in Nature Communications explored the relationship between the cellular landscape and herpes simplex virus type 1 and revealed that both are connected. These research studies are expected to drive advancements in herpes simplex virus treatment during the forecast period.
Moreover, rising investments in innovative vaccines for the treatment of the herpes simplex virus are significantly driving market growth. For instance, Shenzhen Mellow Hope Pharm Industrial. & Rational Vaccines entered into a strategic collaboration to develop herpes vaccines in China.
The Herpes Simplex Virus-1 (HSV-1) segment is anticipated to witness the highest growth in the coming years due to the higher rate of transmission.
Valacyclovir segment accounted for the largest market share owing to the potential for a higher absorption rate of treatment.
Asia Pacific is projected to register the fastest growth during the forecast period, attributable to the risk of contact with infected persons.
The global players include Apotex Inc., Carlsbad Tech, Emcure Pharmaceuticals Ltd., Fresenius Kabi AG, GSK plc, Glenmark Pharmaceuticals Inc., & Novartis AG.
Polaris Market Research has segmented the herpes simplex virus treatment market report based on type, drug, vaccine, route of administration, end-use, and region:
Introduction